Literature DB >> 28352665

Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion.

Dale S Edgerton1, Guillaume Kraft1, Marta Smith1, Ben Farmer1, Phillip E Williams2, Katie C Coate3, Richard L Printz1, Richard M O'Brien1, Alan D Cherrington1.   

Abstract

Insulin can inhibit hepatic glucose production (HGP) by acting directly on the liver as well as indirectly through effects on adipose tissue, pancreas, and brain. While insulin's indirect effects are indisputable, their physiologic role in the suppression of HGP seen in response to increased insulin secretion is not clear. Likewise, the mechanisms by which insulin suppresses lipolysis and pancreatic α cell secretion under physiologic circumstances are also debated. In this study, insulin was infused into the hepatic portal vein to mimic increased insulin secretion, and insulin's indirect liver effects were blocked either individually or collectively. During physiologic hyperinsulinemia, plasma free fatty acid (FFA) and glucagon levels were clamped at basal values and brain insulin action was blocked, but insulin's direct effects on the liver were left intact. Insulin was equally effective at suppressing HGP when its indirect effects were absent as when they were present. In addition, the inhibition of lipolysis, as well as glucagon and insulin secretion, did not require CNS insulin action or decreased plasma FFA. This indicates that the rapid suppression of HGP is attributable to insulin's direct effect on the liver and that its indirect effects are redundant in the context of a physiologic increase in insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28352665      PMCID: PMC5358484          DOI: 10.1172/jci.insight.91863

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  63 in total

Review 1.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Authors:  A D Cherrington
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

2.  Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency.

Authors:  A D Cherrington; J E Liljenquist; G I Shulman; P E Williams; W W Lacy
Journal:  Am J Physiol       Date:  1979-03

3.  Quantifying gluconeogenesis during fasting.

Authors:  V Chandramouli; K Ekberg; W C Schumann; S C Kalhan; J Wahren; B R Landau
Journal:  Am J Physiol       Date:  1997-12

4.  The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog.

Authors:  D K Sindelar; C A Chu; M Rohlie; D W Neal; L L Swift; A D Cherrington
Journal:  Diabetes       Date:  1997-02       Impact factor: 9.461

5.  Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo.

Authors:  Sachin A Paranjape; Owen Chan; Wanling Zhu; Adam M Horblitt; Ewan C McNay; James A Cresswell; Jonathan S Bogan; Rory J McCrimmon; Robert S Sherwin
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

6.  Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production.

Authors:  A Christine Könner; Ruth Janoschek; Leona Plum; Sabine D Jordan; Eva Rother; Xiaosong Ma; Chun Xu; Pablo Enriori; Brigitte Hampel; Gregory S Barsh; C Ronald Kahn; Michael A Cowley; Frances M Ashcroft; Jens C Brüning
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

Review 7.  CNS insulin signaling in the control of energy homeostasis and glucose metabolism - from embryo to old age.

Authors:  Merly C Vogt; Jens C Brüning
Journal:  Trends Endocrinol Metab       Date:  2012-12-19       Impact factor: 12.015

Review 8.  Autocrine regulation of insulin secretion.

Authors:  M Braun; R Ramracheya; P Rorsman
Journal:  Diabetes Obes Metab       Date:  2012-10       Impact factor: 6.577

9.  Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.

Authors:  Michael J Jurczak; Ann-Hwee Lee; Francois R Jornayvaz; Hui-Young Lee; Andreas L Birkenfeld; Blas A Guigni; Mario Kahn; Varman T Samuel; Laurie H Glimcher; Gerald I Shulman
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

10.  Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.

Authors:  Dale S Edgerton; Mary C Moore; Jason J Winnick; Melanie Scott; Ben Farmer; Helle Naver; Claus B Jeppesen; Peter Madsen; Thomas B Kjeldsen; Erica Nishimura; Christian L Brand; Alan D Cherrington
Journal:  Diabetes       Date:  2014-06-19       Impact factor: 9.461

View more
  35 in total

1.  Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.

Authors:  Thomas S Voss; Mikkel H Vendelbo; Ulla Kampmann; Steen B Pedersen; Thomas S Nielsen; Mogens Johannsen; Mads V Svart; Niels Jessen; Niels Møller
Journal:  Diabetologia       Date:  2018-12-01       Impact factor: 10.122

2.  Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice.

Authors:  Innocence Harvey; Erin J Stephenson; JeAnna R Redd; Quynh T Tran; Irit Hochberg; Nathan Qi; Dave Bridges
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

3.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

4.  PAHSAs enhance hepatic and systemic insulin sensitivity through direct and indirect mechanisms.

Authors:  Peng Zhou; Anna Santoro; Odile D Peroni; Andrew T Nelson; Alan Saghatelian; Dionicio Siegel; Barbara B Kahn
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

5.  Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients.

Authors:  Ian Blumer; Lucia M Novak; Steven Edelman; Tricia Santos Cavaiola
Journal:  Clin Diabetes       Date:  2019-10

6.  Morning Hyperinsulinemia Primes the Liver for Glucose Uptake and Glycogen Storage Later in the Day.

Authors:  Mary Courtney Moore; Marta S Smith; Ben Farmer; Katie C Coate; Guillaume Kraft; Masakazu Shiota; Phillip E Williams; Alan D Cherrington
Journal:  Diabetes       Date:  2018-04-17       Impact factor: 9.461

Review 7.  Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes.

Authors:  Ashot Sargsyan; Mark A Herman
Journal:  Curr Diab Rep       Date:  2019-08-03       Impact factor: 4.810

Review 8.  Regulation of Hepatic Metabolism, Recent Advances, and Future Perspectives.

Authors:  Kfir Sharabi; Clint D J Tavares; Pere Puigserver
Journal:  Curr Diab Rep       Date:  2019-09-07       Impact factor: 4.810

Review 9.  Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Trends Pharmacol Sci       Date:  2017-05-24       Impact factor: 14.819

Review 10.  Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention.

Authors:  Rout George Kerry; Gyana Prakash Mahapatra; Ganesh Kumar Maurya; Sushmita Patra; Subhasis Mahari; Gitishree Das; Jayanta Kumar Patra; Sabuj Sahoo
Journal:  Rev Endocr Metab Disord       Date:  2020-10-14       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.